Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139388 | GEO | 2022/09/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (450k DNA methylation microarray)

Project description:To identify novel mechanisms of acquired resistance to ALK inhibitors, we established in vitro models of acquired resistance to ceritinib using H3122 cell. In this study, we examined genome-wide DNA methylation changes during acquired resistance to ceritinib. We also examined the heterogeneity of parental and resistant cells using single cell RNA--seq.

2022-09-20 | GSE139387 | GEO

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (scRNA-seq)

2022-09-20 | GSE139386 | GEO

Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-05-28 | GSE81487 | GEO

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors

Project description:DNA methylation and gene expression changes during acquired resistance to ALK inhibitors

| PRJNA579530 | ENA

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (450k DNA methylation microarray)

Project description:DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (450k DNA methylation microarray)

| PRJNA579537 | ENA

DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (scRNA-seq)

Project description:DNA methylation and gene expression changes during acquired resistance to ALK inhibitors (scRNA-seq)

| PRJNA579536 | ENA

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Project description:Clinical benefit of ALK tyrosine kinase inhibitors (ALK-TKIs) in ALK-rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass-molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA-approved drugs in ALK-TKI-resistant models. Cerivastatin, the rate-limiting enzyme inhibitor of the mevalonate pathway, showed anti-cancer activity against ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic retention and subsequent inactivation of transcriptional co-regulator YAP. The marked induction of YAP-targeted oncogenes (EGFR, AXL, CYR61, and TGFβR2) in resistant cells was abolished by cerivastatin. YAP silencing suppressed tumor growth in resistant cells, patient-derived xenografts, and EML4-ALK transgenic mice, whereas YAP overexpression decreased the responsiveness of parental cells to ALK inhibitor. In matched patient samples before/after ALK inhibitor treatment, nuclear accumulation of YAP was mainly detected in post-treatment samples. High expression of YAP in pretreatment samples was correlated with poor response to ALK-TKIs. Our findings highlight a crucial role of YAP in ALK-TKI resistance and provide a rationale for targeting YAP as a potential treatment option for ALK-rearranged patients with acquired resistance to ALK inhibitors.

| S-EPMC6895608 | biostudies-literature

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Project description:The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant patients, have been developed. Although these ALK-TKIs show an excellent response initially, most patients eventually acquire resistance. Therefore, careful consideration of the resistance mechanisms might lead to superior therapeutic strategies. Here, we summarize the history of ALK-TKIs and their underlying resistance mechanisms in both the preclinical and clinical settings. In addition, we discuss potential future treatment strategies in ALK-TKI-naïve and -resistant patients with lung cancer harboring the EML4-ALK fusion gene.

| S-EPMC4491683 | biostudies-literature

Genome-wide methylation and expression profiling study identifies candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2011-12-20 | GSE28648 | GEO

Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors

Project description:Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors

| PRJNA321744 | ENA